Rhumbline Advisers Has $2.10 Million Stock Holdings in Phreesia, Inc. (NYSE:PHR)

Rhumbline Advisers increased its position in shares of Phreesia, Inc. (NYSE:PHR) by 7.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 83,631 shares of the company’s stock after acquiring an additional 5,756 shares during the period. Rhumbline Advisers owned about 0.14% of Phreesia worth $2,104,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the company. Champlain Investment Partners LLC increased its stake in shares of Phreesia by 4.1% during the 3rd quarter. Champlain Investment Partners LLC now owns 2,503,837 shares of the company’s stock worth $57,062,000 after purchasing an additional 97,847 shares during the last quarter. State Street Corp raised its holdings in Phreesia by 7.1% during the third quarter. State Street Corp now owns 1,327,586 shares of the company’s stock valued at $30,256,000 after buying an additional 88,517 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Phreesia by 4.7% in the third quarter. Geode Capital Management LLC now owns 1,245,797 shares of the company’s stock worth $28,397,000 after buying an additional 55,934 shares during the last quarter. Barclays PLC boosted its stake in shares of Phreesia by 83.6% during the 3rd quarter. Barclays PLC now owns 94,929 shares of the company’s stock worth $2,163,000 after acquiring an additional 43,225 shares in the last quarter. Finally, Franklin Resources Inc. increased its holdings in shares of Phreesia by 3.0% during the 3rd quarter. Franklin Resources Inc. now owns 1,497,631 shares of the company’s stock valued at $31,495,000 after acquiring an additional 42,973 shares during the last quarter. Institutional investors and hedge funds own 92.10% of the company’s stock.

Insider Activity at Phreesia

In related news, SVP David Linetsky sold 11,853 shares of the firm’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $24.85, for a total transaction of $294,547.05. Following the completion of the transaction, the senior vice president now owns 188,354 shares in the company, valued at $4,680,596.90. This trade represents a 5.92 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel Allison C. Hoffman sold 3,496 shares of the company’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $29.72, for a total value of $103,901.12. Following the completion of the sale, the general counsel now owns 142,630 shares in the company, valued at $4,238,963.60. This trade represents a 2.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 195,740 shares of company stock valued at $5,441,409 over the last quarter. 5.80% of the stock is owned by company insiders.

Phreesia Trading Down 2.8 %

Shares of PHR opened at $25.80 on Tuesday. The stock’s 50-day moving average price is $27.51 and its 200 day moving average price is $24.02. The company has a quick ratio of 1.74, a current ratio of 1.74 and a debt-to-equity ratio of 0.04. Phreesia, Inc. has a 12-month low of $17.07 and a 12-month high of $30.53. The firm has a market capitalization of $1.50 billion, a price-to-earnings ratio of -17.55 and a beta of 0.96.

Phreesia (NYSE:PHR) last posted its quarterly earnings results on Monday, December 9th. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.04. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. The firm had revenue of $106.80 million for the quarter, compared to the consensus estimate of $106.33 million. During the same quarter in the previous year, the company earned ($0.58) earnings per share. The business’s revenue was up 16.6% compared to the same quarter last year. As a group, research analysts predict that Phreesia, Inc. will post -1.1 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Piper Sandler restated an “overweight” rating and issued a $33.00 target price (up from $31.00) on shares of Phreesia in a report on Wednesday, January 29th. KeyCorp boosted their price objective on shares of Phreesia from $28.00 to $30.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 8th. Royal Bank of Canada upgraded shares of Phreesia from a “sector perform” rating to an “outperform” rating and raised their target price for the company from $24.00 to $32.00 in a research note on Wednesday, January 8th. JMP Securities reissued a “market outperform” rating and set a $30.00 target price on shares of Phreesia in a research report on Tuesday, December 10th. Finally, Citigroup raised their price target on Phreesia from $31.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, January 10th. Thirteen investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Phreesia presently has an average rating of “Buy” and an average target price of $31.15.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.